Bibliografía
1. Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmun Rev . NIH Public Access; 2014;13(4–5):441–4.
2. Parés A. Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid? Clin Liver Dis; 2014;3(2):29–33.
3. Nguyen DL, Juran BD, Lazaridis KN. Primary biliary cirrhosis. Best Pract Res Clin Gastroenterol. 2010;24(5):647–54.
4. Corpechot C, Chrétien Y, Chazouillères O, et.al. Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol. 2010;53(1):162–9.
5. Orphanet Report Series. Prevalencia de las enfermedades raras : Datos bibliográficos Enfermedades listadas por orden de prevalencia o incidencia decreciente o por número de casos publicados [Internet]. [cited 2016 Dec 12]. Available from: http://www.orpha.net/orphacom/cahiers/docs/ES/Prevalencia_de_las_enfermedades_raras_por_prevalencia_decreciente_o_casos.pdf
6. Juran BD, Lazaridis KN. Environmental factors in primary biliary cirrhosis. Semin Liver Dis. NIH Public Access; 2014;34(3):265–72.
7. Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis. 2008 ;3(1):1.
8. Kurtovic J, Riordan SM, Williams R. The natural history of asymptomatic primary biliary cirrhosis. QJM An Int J Med. Oxford University Press; 2005;98(5):331–6. A
9. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009 ;50(1):291–308.
10. Al-Harthy N, Kumagi T. Natural history and management of primary biliary cirrhosis. Hepat Med. Dove Press; 2012;4:61–71.
11. Leuschner U, Manns M-P, Eisebitt R. Ursodeoxycholic Acid in the Therapy for Primary Biliary Cirrhosis: Effects on Progression and Prognosis. Z Gastroenterol. 2005;43(9):1051–9.
12. Metcalf J V, Mitchison HC, Palmer JM, et.al. Natural history of early primary biliary cirrhosis. Lancet. 1996;348(9039):1399–402.
13. Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871–7.
14. Lammers WJ, van Buuren HR, Hirschfield GM, et.al. Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology. 2014;147(6):1338–1349.e5.
15. Poupon RE, Lindor KD, Cauch-Dudek K, et.al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997 Sep;113(3):884–90.
16. Corpechot C, Carrat F, Bahr A, et.al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128(2):297–303.
17. Angulo P, Lindor KD, Therneau TM, et.al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999;19(2):115–21.
18. Carbone M, Mells GF, Pells G, et.al. Sex and Age Are Determinants of the Clinical Phenotype of Primary Biliary Cirrhosis and Response to Ursodeoxycholic Acid. Gastroenterology. 2013;144(3):560–569.e7.
19. Kumagi T, Guindi M, Fischer SE, et.al. Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis. Am J Gastroenterol. 2010;105(10):2186–94.
20. Momah N, Silveira MG, Jorgensen R, et.al. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int. 2012;32(5):790–5.
21. Parés A, Caballería L, Rodés J. Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid. Gastroenterology. 2006;130(3):715–20.
22. Galiè N, Humbert M, Vachiery J-L, et.al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016 Jan;37(1):67–119.
23. Kashyap R, Safadjou S, Chen R, et.al. Living Donor and Deceased Donor Liver Transplantation for Autoimmune and Cholestatic Liver Diseases—An Analysis of the UNOS Database. J Gastrointest Surg. 2010;14(9):1362–9.
24. Nevens F, Andreone P, Mazzella G, et.al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. Massachusetts Medical Society; 2016;375(7):631–43.
25. Akamatsu N, Sugawara Y. Primary biliary cirrhosis and liver transplantation. Intractable rare Dis Res. International Advancement Center for Medicine & Health Research Co.; 2012;1(2):66–80.
26. Huang Y-Q. Recent advances in the diagnosis and treatment of primary biliary cholangitis. World J Hepatol. Baishideng Publishing Group Inc; 2016;8(33):1419–41.
27. Chalifoux SL, Konyn PG, Choi G, et.al. Extrahepatic Manifestations of Primary Biliary Cholangitis. Gut Liver. Editorial Office of Gut and Liver; 2017;11(6):771–80.
28. EMA (European Medicines Agency). Summary of Product Characteristics. Ocaliva. 2016 [cited 2017 Nov 12];1–26. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004093/WC500218418.pdf
29. Ramalle-Gómara E, Ruiz E, Quiñones C, et.al. General knowledge and opinion of future health care and non-health care professionals on rare diseases. J Eval Clin Pract. 2015;21(2):198–201.
30. Pla X, Vergara M, Gil M, et.al. Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community. Eur J Gastroenterol Hepatol. 2007;19(10):859–64.
31. Registro Nacional de Enfermedades colestásicas y autoinmunes hepáticas (ColHai) | AEEH [Internet]. [cited 2017 Nov 28]. Available from: http://aeeh.es/2016/11/registro-nacional-de-enfermedades-colestasicas-y-autoinmunes-hepaticas-colhai/
32. Caballero Plasencia AM, López Callejas C, Valenzuela Barranco M, et.al. [Epidemiology of primary biliary cirrhosis in the South area of Granada]. Med Clin (Barc). 1991;96(13):481–5.
33. Moreno Sánchez D, Cassinello Ogea C, González Blanco P, et.al. [Epidemiology of primary biliary cirrhosis in southern Madrid]. Med Clin (Barc). 1990;94(15):564–9.
34. Borda F, Huarte MP, Zozaya JM, et.al. [Primary biliary cirrhosis in Navarra]. An Med Interna. 1989;6(2):63–6.
35. Parés A, Bruguera M, Rodés J, et.al. [Epidemiology of primary biliary cirrhosis in Cataluna]. Med Clin (Barc). 1984;82(6):237–41.
36. Rodrigo Sáez L, Valerdiz Casasola CS, Rodríguez García M, et.al. [Epidemiology of primary biliary cirrhosis in Asturias]. Med Clin (Barc). 1987;88(12):486–9.
37. de Villiers MR, de Villiers PJT, Kent AP. The Delphi technique in health sciences education research. Med Teach. 2005;27(7):639–43.
38. Albi España Asociación para la lucha contra las enfermedades biliares inflamatorias [Internet]. [cited 2017 Nov 28]. Available from: http://www.albi-espana.org/
39. AEEH | Asociación Española para el Estudio del Hígado [Internet]. [cited 2017 Nov 28]. Available from: http://aeeh.es/
40. Orphanet. Orphan Drugs in Europe [Internet]. [cited 2017 Feb 3]. Available from: http://www.orpha.net/consor4.01/www/cgi-bin/Education_AboutOrphanDrugs.php?lng=EN&stapage=ST_EDUCATION_EDUCATION_ABOUTORPHANDRUGS_EUR
41. INE. Instituto Nacional de Estadística [Internet]. [cited 2017 Jun 13]. Available from: http://www.ine.es/
42. Boonstra K, Kunst AE, Stadhouders PH, et.al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int. 2014;34(6):e31–8.
43. Podda M, Selmi C, Lleo A, et.al. The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. J Autoimmun. 2013;46:81–7.
44. Rautiainen H, Salomaa V, Niemelä S, et.al. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol. 2007;42(11):1347–53.
45. Wang L, Gershwin ME, Wang F-S. Primary biliary cholangitis in China. Curr Opin Gastroenterol. 2016;32(3):1. A
46. Myers RP, Shaheen AAM, Fong A, et.al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population-based study. Hepatology. 2009;50(6):1884–92.
47. Jones DEJ, Sutcliffe K, Pairman J, et.al. An integrated care pathway improves quality of life in Primary Biliary Cirrhosis. QJM. 2008;101(7):535–43.
48. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67.
49. Comisión Interministerial de Precios de los Medicamentos. Nota informativa de la reunión de la comisión interministerial de precios de los medicamentos. Sesión 177 de 6 de noviembre de 2017. 2017 [cited 2018 Mar 20]; Available from: https://www.msssi.gob.es/profesionales/farmacia/pdf/ACUERDOS_DE_LA_CIPM_177_web.pdf
50. AEMPS. Ficha técnica Ocaliva 5 mg comprimidos recubiertos con película [Internet]. [cited 2018 Mar 15]. Available from: https://cima.aemps.es/cima/dochtml/ft/1161139001/FT_1161139001.html